ArticleBMC nephrology2026
Geographic remoteness and chronic kidney disease outcomes: a population-based cohort study using linked pathology data.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundEvidence on inequities in long-term chronic kidney disease (CKD) outcomes from population-based cohorts is limited, and geographic inequities across the full spectrum of CKD in Australia remain under-examined. We investigated how clinical outcomes and healthcare utilisation vary by geographic remoteness in Western Australia (WA), leveraging a state-wide linked pathology dataset spanning over 15 years.
methodsA cohort study in WA of adults (≥ 18 years) with incident CKD (2010–2017) identified from pathology data linked to hospital, emergency department (ED), and death records. CKD was defined by two estimated glomerular filtration rate (eGFR) measurements, 3–12 months apart, within the same CKD stage (3a: 45–59, 3b: 30–44, or 4: 15–29 mL/min/1.73 m²). Clinical outcomes included early CKD presentation (stage 3a), CKD progression (to a higher CKD stage or kidney failure based on eGFR), kidney replacement therapy (KRT), and all-cause mortality. Healthcare utilisation outcomes included 3-year frequency of hospital separations (completed admitted hospital stays), ED presentations, and serum creatinine testing. Associations with geographic remoteness were examined using multivariable logistic, Cox proportional hazards, and negative binomial regression, adjusting for age, sex, comorbidities, and CKD stage at cohort entry.
resultsAmong 78,244 individuals (58,845 major city; 15,990 regional; 3,409 remote), remote residents had lower odds of early presentation (adjusted odds ratio [aOR], 0.87; 95% confidence interval [CI], 0.79–0.95) and higher hazards of progression (adjusted hazard ratio [aHR], 1.15; 95% CI, 1.09–1.22), KRT (aHR, 1.94; 95% CI, 1.71–2.20), and mortality (aHR, 1.12; 95% CI, 1.06–1.19) compared with major city residents. Differences were most pronounced among those aged 18–60 years (early presentation: aOR, 0.76; 95% CI, 0.64–0.89; mortality: aHR, 1.31; 95% CI, 1.15–1.49), and 18–60 years with diabetes (progression: aHR, 1.88; 95% CI, 1.70–2.09; KRT: aHR, 2.67; 95% CI, 2.27–3.14). Healthcare utilisation was particularly elevated in the remote 18–60-year group with diabetes (ED presentations: adjusted incidence rate ratio [aIRR], 3.01; 95% CI, 2.73–3.31; hospitalisations: aIRR, 2.29; 95% CI, 2.10–2.50; serum creatinine testing: aIRR, 1.16; 95% CI, 1.07–1.26). Regional residents had comparable clinical outcomes to major city residents.
conclusionsPopulation-level data from WA shows significant geographic disparities in CKD outcomes. Determining and addressing drivers of these disparities, especially among remote adults aged 18–60 years with diabetes, should be a priority for equitable kidney health policy and service planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.